- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Synthesis of Coagulation Factor Xa Inhibitor Apixaban ; volume:18 ; number:12 ; year:2022 ; pages:1377
Synfacts ; 18, Heft 12 (2022), 1377
- DOI
-
10.1055/s-0042-1753104
- URN
-
urn:nbn:de:101:1-2023011210590047291218
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Other Objects (12)
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Pharmakokinetik und Interaktionen von gemeinsam verabreichten mikrodosierten Faktor-Xa-Inhibitoren Rivaroxaban, Apixaban und Edoxaban
Roles of factor Xa beyond coagulation
Roles of factor Xa beyond coagulation
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Bioassay-directed fractionation of a blood coagulation factor Xa inhibitor, betulinic acid from Lycopus lucidus
The role of coagulation factor Xa in emergency hematopoiesis
Thrombin and factor Xa link the coagulation system with liver fibrosis
Protein‐Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background‐Free Amidation Reaction
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
Entwicklung eines Tiermodells der längerfristigen Antikoagulation mit Vitamin-K-Antagonisten (Warfarin) und Faktor-Xa-Inhibitoren (Apixaban) zur Risikoabschätzung und zur Charakterisierung der Pathophysiologie komplikativer Hirnblutungen
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Pharmakokinetik und Interaktionen von gemeinsam verabreichten mikrodosierten Faktor-Xa-Inhibitoren Rivaroxaban, Apixaban und Edoxaban
Roles of factor Xa beyond coagulation
Roles of factor Xa beyond coagulation
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Bioassay-directed fractionation of a blood coagulation factor Xa inhibitor, betulinic acid from Lycopus lucidus
The role of coagulation factor Xa in emergency hematopoiesis
Thrombin and factor Xa link the coagulation system with liver fibrosis
Protein‐Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background‐Free Amidation Reaction
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
Entwicklung eines Tiermodells der längerfristigen Antikoagulation mit Vitamin-K-Antagonisten (Warfarin) und Faktor-Xa-Inhibitoren (Apixaban) zur Risikoabschätzung und zur Charakterisierung der Pathophysiologie komplikativer Hirnblutungen
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Pharmakokinetik und Interaktionen von gemeinsam verabreichten mikrodosierten Faktor-Xa-Inhibitoren Rivaroxaban, Apixaban und Edoxaban
Roles of factor Xa beyond coagulation
Roles of factor Xa beyond coagulation
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Bioassay-directed fractionation of a blood coagulation factor Xa inhibitor, betulinic acid from Lycopus lucidus
The role of coagulation factor Xa in emergency hematopoiesis
Thrombin and factor Xa link the coagulation system with liver fibrosis
Protein‐Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background‐Free Amidation Reaction
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
Entwicklung eines Tiermodells der längerfristigen Antikoagulation mit Vitamin-K-Antagonisten (Warfarin) und Faktor-Xa-Inhibitoren (Apixaban) zur Risikoabschätzung und zur Charakterisierung der Pathophysiologie komplikativer Hirnblutungen